Sharon Bio-Medicine is an API manufacturer based in India. It holds 5 active US drug master files and one valid CEP across a filed portfolio of 7 molecules. Its filings concentrate with DAV (Vietnam), ARCSA (EC) and MINSA (CR). Its GMP standing is certified by EMA and MHRA (UK). Its most recent recorded inspection, by US FDA, closed on 22 February 2019 as VAI. Customs aggregates show $21.8M of exports covering 1,058 molecules to 27 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| UTTARAKHAND, India | Not on file |
| Navi Mumbai, India | Not on file |
| Raigad, India | 3004455093 |
| Dehradun, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Trimetazidine Dihydrochloride | EDQM, SFDA (Saudi Arabia) | 2 |
| Eperisone | SFDA (Saudi Arabia) | 1 |
| Ketoconazole | US FDA | 1 |
| Memantine | US FDA | 1 |
| Moxifloxacin | US FDA | 1 |
| Nifedipine | US FDA | 1 |
| Telmisartan | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| DAV (Vietnam) | 9 | None |
| ARCSA (EC) | 3 | None |
| MINSA (CR) | 2 | None |
| EMA | None | 1 |
| MHRA (UK) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $3.2M | 15 |
| 2025 | Not reported | $21.8M | 27 |
| 2024 | Not reported | $17.5M | 28 |
| 2023 | Not reported | $15.4M | 25 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Sharon Bio-Medicine comes back tiered against every other supplier able to file there.
Start for free